graft versus host disease


Also found in: Dictionary, Acronyms.

graft ver·sus host dis·ease (GVHD),

an incompatibility reaction (that may be fatal) in a subject (host) of low immunologic competence who has been the recipient of immunologically competent lymphoid tissue from a donor who is immunologically different from the recipient; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess an antigen not found in the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 7-30 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Synonym(s): GVH disease

Graft versus host disease

A life-threatening complication of bone marrow transplants in which the donated marrow causes an immune reaction against the recipient's body.
References in periodicals archive ?
The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism.
Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD).
Graft versus Host Disease (GvHD) is one of the potentially fatal complications of hematopoietic stem cell transplantation (HCT).
The companies entered into the original license agreement in August 2003, granting JCR the right to commercialize a stem cell drug in Japan designed to treat the effects of Graft versus Host Disease (GvHD) in patients undergoing bone marrow transplantation to treat leukemia.
Overly aggressive immune responses have become associated with many serious diseases such as arthritis, graft versus host disease, inflammatory bowel disease, and other conditions.
Osiris recently became the first company to receive Fast Track designation from FDA for a similar stem cell product, Prochymal(TM), for the treatment of graft versus host disease in cancer patients.
Completion of the pivotal phase III clinical trial for lead product orBec(R) (beclomethasone 17, 21-dipropionate) for the treatment of intestinal graft versus host disease.
Moreover, clinicians have reported positive results using ATG-FRESENIUS S for conditioning regimens and prevention of graft versus host disease in bone marrow transplantation.
His extensive licensing experience will be essential in building value in our biotherapeutic programs as we are eagerly awaiting the results of our pivotal Phase III clinical trial of orBec(R) in intestinal graft versus host disease.